News & Analysis as of

NIDA

McCarter & English, LLP

DEA’s Plan to Reschedule Cannabis: Implications and Insights

Earlier this week, the Department of Justice proposed reclassifying cannabis from Schedule I to Schedule III under the Controlled Substances Act. The move follows an August 2023 recommendation from the Department of Health...more

McGlinchey Stafford

Is THCA Legal? The State Line is the Bottom Line

McGlinchey Stafford on

Tetrahydrocannabinolic acid (THCA) is one of the most misunderstood and controversial cannabinoids in the Cannabis sativa (cannabis) plant. While booming in popularity, THCA is also a high-risk cannabinoid from a legal...more

Amundsen Davis LLC

Historic Cannabis Rescheduling on the Horizon? It's Up to the DEA Now

Amundsen Davis LLC on

In October of 2022, the Biden Administration started an official cannabis policy review process, which began with granting pardons to all people convicted of simple cannabis possession under federal law. At the time, this was...more

Perkins Coie

FDA Releases Guidance on Clinical Research into Cannabis-Derived Drugs

Perkins Coie on

The U.S. Food and Drug Administration (FDA) recently released new guidance on sourcing and product quality to companies conducting clinical research related to the development of human drugs involving cannabis or...more

Dunlap Bennett & Ludwig PLLC

Researching Potential Medical Benefits of Cannabis Moves a Step Closer – sort of.

Cannabis legalization advocates are quick to point out a Catch-22 in current legalization debates. On one hand, Cannabis is a Schedule 1 drug under the Controlled Substances Act....more

Vicente LLP

NIDA Monopoly is Over: New DEA-Registered Cannabis Growers Can Supply Researchers with Product

Vicente LLP on

It seems like every day I read a new story about legislators, high-ranking federal officials, and frustrated advocates of marijuana research complaining that researchers still can't study the actual marijuana that people are...more

Womble Bond Dickinson

DEA Set to Allow More Facilities to Produce Marijuana for Research: A Victory for Cannabis Growers, Researchers and the DEA?

Womble Bond Dickinson on

Although many states have legalized marijuana for medicinal and/or recreational use, when it comes to using marijuana in a research setting, sources have been very limited.  The US Drug Enforcement Administration (DEA) has...more

Wiley Rein LLP

Federal Agency COVID-19 Responses - February 12, 2021

Wiley Rein LLP on

*Wiley continues to closely monitor the COVID-19 crisis and will update this list as new information is available. This alert was originally published on March 25, 2020, and last updated February 12, 2021. ...more

Wiley Rein LLP

Federal Agency COVID-19 Responses - January 20, 2021

Wiley Rein LLP on

*Wiley continues to closely monitor the COVID-19 crisis and will update this list as new information is available. This alert was originally published on March 25, 2020, and last updated January 20, 2021. ...more

Wiley Rein LLP

Federal Agency COVID-19 Responses - January 4, 2021

Wiley Rein LLP on

*Wiley continues to closely monitor the COVID-19 crisis and will update this list as new information is available. This alert was originally published on March 25, 2020, and last updated January 4, 2021. ...more

Sheppard Mullin Richter & Hampton LLP

House Of Representatives Passes A Cannabis Bill That Republicans And Democrats Can Agree On

On December 9, 2020, the House of Representatives passed H.R. 3797—The Medical Marijuana Research Act (the “Bill”), expanding access to cannabis for medical research purposes. In so doing, a bipartisan majority of members of...more

Saul Ewing LLP

On Heels of Senate’s Adoption of Cannabis Research Bill, DEA Issues Rule to License More Research Cannabis Growers

Saul Ewing LLP on

On December 18, 2020, just three days after the U.S. Senate adopted the Cannabidiol and Marihuana Research Expansion Act (CMREA or the Act) (more on this below), the U.S. Drug Enforcement Administration (DEA or the...more

Wiley Rein LLP

Federal Agency COVID-19 Responses - December 2020 #2

Wiley Rein LLP on

*Wiley continues to closely monitor the COVID-19 crisis and will update this list as new information is available. This alert was originally published on March 25, 2020, and last updated December 18, 2020. ...more

Wiley Rein LLP

Federal Agency COVID-19 Responses - December 4, 2020

Wiley Rein LLP on

*Wiley continues to closely monitor the COVID-19 crisis and will update this list as new information is available. This alert was originally published on March 25, 2020, and last updated December 4, 2020. ...more

Wiley Rein LLP

Federal Agency COVID-19 Responses (Update #2)

Wiley Rein LLP on

*Wiley continues to closely monitor the COVID-19 crisis and will update this list as new information is available. This alert was originally published on March 25, 2020, and last updated November 13, 2020....more

Wiley Rein LLP

Federal Agency COVID-19 Responses

Wiley Rein LLP on

*Wiley continues to closely monitor the COVID-19 crisis and will update this list as new information is available. This alert was originally published on March 25, 2020, and last updated October 9, 2020. 1. Administration...more

Womble Bond Dickinson

FDA Issues Guidance on Clinical Research for Cannabis Drugs

Womble Bond Dickinson on

On Tuesday, July 21, 2020, the U.S. Food and Drug Administration (FDA) released a new draft guidance, Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research. The draft guidance is intended to...more

Kelley Drye & Warren LLP

House Subcommittee Holds Hearing on Current Cannabis Policies

On January 15, the Subcommittee on Health of the Committee on Energy and Commerce held its first ever legislative hearing to address federal cannabis policies. The subcommittee invited witness from three different agencies...more

Health Care Compliance Association (HCCA)

Report on Research Compliance 17, no. 1. In This Month's E-News: January 2020

Report on Research Compliance 17, no. 1 (January 2020) - ? A man from Richland, Washington, is facing life in prison after being convicted of 47 counts of fraud for staging clinical trials that purportedly enrolled dozens of...more

19 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide